Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDX3X | O00571 | 10/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.42 |
| ▸ | RXRA | P19793 | 2/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | F9 | P00740 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2857576 | 0.92 | KMT2A (0.46) | DDX3XNOTUMRXRAGRIN1GRIN2B | |
| SCHEMBL2853567 | 0.91 | NOTUM (0.51) | DDX3XNOTUMCA1CA2CA4 | |
| SCHEMBL2854474 | 0.89 | DDX3X (0.53) | DDX3XNOTUMCA1CA2CA4 | |
| SCHEMBL2856972 | 0.88 | DDX3X (0.47) | DDX3XNOTUMCA1CA2CA4 | |
| SCHEMBL2852561 | 0.87 | NOTUM (0.48) | DDX3XNOTUMCA1CA2CA4 | |
| SCHEMBL13513478 | 0.85 | DDX3X (0.48) | DDX3XNOTUMCA1CA2CA4 | |
| SCHEMBL2856650 | 0.85 | NOTUM (0.47) | DDX3XNOTUMRXRAGRIN1GRIN2B | |
| SCHEMBL2855204 | 0.85 | DDX3X (0.47) | DDX3XNOTUMRXRAGRIN1GRIN2B | |
| SCHEMBL2855225 | 0.85 | F9 (0.46) | DDX3XNOTUMCA1CA2CA4 | |
| SCHEMBL2852017 | 0.85 | DDX3X (0.49) | DDX3XNOTUMF9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828148-B1 | TRIAZOLE SUBSTITUTED AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA AS (DK) | 2010-01-20 | — | — | EP | claimed |
| EP-1828148-A1 | TRIAZOLE SUBSTITUTED AMINOBENZOPHENONE COMPOUNDS | Leo Pharma A/S (DK) | 2007-09-05 | — | — | EP | claimed |
| WO-2006063585-A1 | TRIAZOLE SUBSTITUTED AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA A/S (DK) | 2006-06-22 | — | — | WO | claimed |
| US-20060128766-A1 | Triazole substituted aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2006-06-15 | — | — | US | claimed |
| US-8293772-B2 | Triazole substituted aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2012-10-23 | — | — | US | disclosed |
| US-8293772-B2 | Triazole substituted aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2012-10-23 | — | — | US | disclosed |
| EP-1828148-B1 | TRIAZOLE SUBSTITUTED AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA AS (DK) | 2010-01-20 | — | — | EP | disclosed |
| EP-1828148-A1 | TRIAZOLE SUBSTITUTED AMINOBENZOPHENONE COMPOUNDS | Leo Pharma A/S (DK) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006063585-A1 | TRIAZOLE SUBSTITUTED AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA A/S (DK) | 2006-06-22 | — | — | WO | disclosed |
| US-20060128766-A1 | Triazole substituted aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128766-A1 | Triazole substituted aminobenzophenone compounds | NFKBIA, UACA, CYP1B1 | DDX3X 3101/4885NOTUM 3513/4885RXRA 2023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.